Cabot Co. (NYSE:CBT) Shares Sold by Kennedy Capital Management LLC

Kennedy Capital Management LLC reduced its stake in Cabot Co. (NYSE:CBT - Free Report) by 40.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 8,573 shares of the specialty chemicals company's stock after selling 5,823 shares during the quarter. Kennedy Capital Management LLC's holdings in Cabot were worth $783,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of CBT. Neuberger Berman Group LLC grew its stake in Cabot by 1.2% in the 4th quarter. Neuberger Berman Group LLC now owns 18,238 shares of the specialty chemicals company's stock worth $1,665,000 after acquiring an additional 212 shares during the period. LSV Asset Management raised its position in shares of Cabot by 40.5% in the 4th quarter. LSV Asset Management now owns 136,600 shares of the specialty chemicals company's stock worth $12,473,000 after buying an additional 39,400 shares during the period. Capital Fund Management S.A. purchased a new position in shares of Cabot in the 4th quarter worth about $2,022,000. Raymond James Financial Inc. acquired a new position in Cabot during the fourth quarter valued at approximately $5,057,000. Finally, Advisory Services Network LLC acquired a new position in shares of Cabot during the 4th quarter valued at $625,000. 93.18% of the stock is owned by institutional investors and hedge funds.

Cabot Stock Performance

CBT traded up $0.08 during trading hours on Friday, hitting $78.40. 338,411 shares of the stock were exchanged, compared to its average volume of 387,326. Cabot Co. has a 12 month low of $73.63 and a 12 month high of $117.46. The stock has a 50-day simple moving average of $82.71 and a 200-day simple moving average of $94.90. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.00 and a quick ratio of 1.29. The stock has a market cap of $4.25 billion, a price-to-earnings ratio of 10.41, a price-to-earnings-growth ratio of 0.74 and a beta of 1.04.

Cabot (NYSE:CBT - Get Free Report) last released its quarterly earnings data on Monday, February 3rd. The specialty chemicals company reported $1.76 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.74 by $0.02. Cabot had a return on equity of 26.79% and a net margin of 10.60%. Analysts anticipate that Cabot Co. will post 7.57 earnings per share for the current year.

Analysts Set New Price Targets

CBT has been the topic of several recent research reports. JPMorgan Chase & Co. reduced their price target on Cabot from $105.00 to $85.00 and set an "underweight" rating on the stock in a research report on Friday, February 21st. Mizuho decreased their target price on shares of Cabot from $122.00 to $110.00 and set an "outperform" rating for the company in a research note on Tuesday, January 7th. UBS Group dropped their price target on shares of Cabot from $93.00 to $83.00 and set a "neutral" rating on the stock in a research note on Monday, April 7th. Finally, StockNews.com upgraded Cabot from a "hold" rating to a "buy" rating in a report on Thursday.

Cabot Profile

Cabot Corporation operates as a specialty chemicals and performance materials company. The company operates through two segments, Reinforcement Materials and Performance Chemicals. It offers reinforcing carbons that are used in tires as a rubber reinforcing agent and performance additive, as well as in industrial products, such as hoses, belts, extruded profiles, and molded goods; and engineered elastomer composites solutions.